Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.22.02613 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrospective Study of Pediatric Sinonasal Tumors in a Tertiary Hospital Setting.
Am J Case Rep
September 2025
Department of Otolaryngology - Head and Neck Surgery, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
BACKGROUND Pediatric sinonasal tumors are rare, accounting for about 4% of all pediatric head and neck neoplasms. Due to their nonspecific symptoms such as nasal obstruction, epistaxis, and facial pain, these tumors often present diagnostic challenges and lead to delays in managment. Early and accurate diagnosis is crucial to optimize clinical outcomes.
View Article and Find Full Text PDFRelapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG).
Br J Cancer
September 2025
Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
At least one-third of patients with localized rhabdomyosarcoma (RMS) and 60-70% of patients with metastatic RMS experience progressive disease or relapse. Following relapse, outcomes generally remain poor with limited treatment options and a high risk of subsequent recurrence. Optimal treatment requires a multidisciplinary approach incorporating chemotherapy with local control.
View Article and Find Full Text PDFPAX3-FOXO1 Drives Targetable Cell State-Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma.
Cancer Res
September 2025
Memorial Sloan Kettering Cancer Center, New York, United States.
PAX3-FOXO1, an oncogenic transcription factor, drives a particularly aggressive subtype of rhabdomyosarcoma (RMS) by enforcing gene expression programs that support malignant cell states. Here, we showed that PAX3-FOXO1+ RMS cells exhibit altered pyrimidine metabolism and increased dependence on enzymes involved in de novo pyrimidine synthesis, including dihydrofolate reductase (DHFR). Consequently, PAX3-FOXO1+ cells displayed increased sensitivity to inhibition of DHFR by the chemotherapeutic drug methotrexate, and this dependence was rescued by provision of pyrimidine nucleotides.
View Article and Find Full Text PDFDental Adverse Effects Following Multimodality Treatment for Head and Neck Rhabdomyosarcoma: Results of a Trans-Atlantic Multicentre Study.
Pediatr Blood Cancer
September 2025
Princess Máxima Centre For Paediatric Oncology, Utrecht, The Netherlands.
Introduction: As survival of paediatric cancer improves, more emphasis is placed on late adverse effects. However, the dental and periodontal adverse effects of cancer treatments in children remain an underinvestigated complication. This study aims to investigate the prevalence of late clinical dental adverse effects (cDAE) in survivors of paediatric head and neck rhabdomyosarcoma (HNRMS).
View Article and Find Full Text PDFASO Visual Abstract: Surgical Lymph Node Staging in Extremity Rhabdomyosarcoma: The EpSSG RMS 2005 Trial Experience.
Ann Surg Oncol
September 2025
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.